{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:52:07Z","timestamp":1790218327419,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,5,4]],"date-time":"2019-05-04T00:00:00Z","timestamp":1556928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sanofi Genzyme and Regeneron Pharmaceuticals, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40262-019-00765-1","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T13:24:22Z","timestamp":1557149062000},"page":"1455-1467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis"],"prefix":"10.1007","volume":"58","author":[{"given":"Christine","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Paccaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanaja","family":"Kanamaluru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,4]]},"reference":[{"issue":"1","key":"765_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","volume":"74","author":"T Kishimoto","year":"1989","unstructured":"Kishimoto T. The biology of interleukin-6. Blood. 1989;74(1):1\u201310.","journal-title":"Blood"},{"issue":"4","key":"765_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/CS20110340","volume":"122","author":"M Mihara","year":"2012","unstructured":"Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6\/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122(4):143\u201359.","journal-title":"Clin Sci (Lond)"},{"key":"765_CR3","doi-asserted-by":"publisher","first-page":"698313","DOI":"10.1155\/2014\/698313","volume":"2014","author":"Y Yoshida","year":"2014","unstructured":"Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313.","journal-title":"Biomed Res Int"},{"issue":"5","key":"765_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","volume":"38","author":"GW Kim","year":"2015","unstructured":"Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res. 2015;38(5):575\u201384.","journal-title":"Arch Pharm Res."},{"issue":"1","key":"765_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/rheumatology\/kep329","volume":"49","author":"JM Dayer","year":"2010","unstructured":"Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49(1):15\u201324.","journal-title":"Rheumatology (Oxford)"},{"key":"765_CR6","unstructured":"Kevzara. US prescribing information. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761037s000lbl.pdf\n\n. Accessed 6 Apr 2019."},{"key":"765_CR7","unstructured":"Kevzara. Summary of product characteristics. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004254\/WC500230068.pdf\n\n. Accessed 6 Apr 2019."},{"issue":"9877","key":"765_CR8","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541\u201350.","journal-title":"Lancet"},{"issue":"Suppl. 10","key":"765_CR9","first-page":"971","volume":"67","author":"P Emery","year":"2015","unstructured":"Emery P, Rondon J, Garg A, van Hoogstraten H, Graham N, Liu M, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with RA [abstract no. 971]. Arthritis Rheumatol. 2015;67(Suppl. 10):971.","journal-title":"Arthritis Rheumatol."},{"key":"765_CR10","unstructured":"Belomestnov P, Hamilton JD, DiCioccio AT, Jasson M, Radin AR. Sarilumab, a subcutaneously administered fully human monoclonal antibody inhibitor of the IL-6 receptor: pharmacokinetic profile and its relationship to changes in pharmacodynamic markers in patients with rheumatoid arthritis [abstract no. 1337]. ACR\/ARHP Annual Meeting; 9\u201314 Nov, 2012; Washington, DC."},{"issue":"6","key":"765_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/psp4.41","volume":"4","author":"P Dua","year":"2015","unstructured":"Dua P, Hawkins E, van der Graaf PH. A tutorial on target-mediated drug disposition (TMDD) models. CPT Pharmacometrics Syst Pharmacol. 2015;4(6):324\u201337.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"1","key":"765_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10928-009-9142-8","volume":"37","author":"X Yan","year":"2010","unstructured":"Yan X, Mager DE, Krzyzanski W. Selection between Michaelis\u2013Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2010;37(1):25\u201347.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"765_CR13","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.4155\/bio.15.66","volume":"7","author":"M Andisik","year":"2015","unstructured":"Andisik M, DeStefano L, Stefan C, Gathani M, Laurino K, Lai V, et al. Effects of blood processing and sample storage on the stability of biotherapeutics and anti-drug antibodies. Bioanalysis. 2015;7(11):1325\u201335.","journal-title":"Bioanalysis."},{"key":"765_CR14","first-page":"37","volume":"351","author":"US Food and Drug Administration","year":"2015","unstructured":"US Food and Drug Administration. Center for drug evaluation and research. Clin Pharmacol Biopharm. 2015;351:37.","journal-title":"Clin Pharmacol Biopharm."},{"issue":"1","key":"765_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51\u201364.","journal-title":"Comput Methods Programs Biomed"},{"key":"765_CR16","unstructured":"Zhaoling Meng Z, Sebastien B, Sun S, Rigaux-Lampe C, Paccaly A, Xu C, et al., editors. Exposure-response modeling for sarilumab dose regimens [abstract no. 7285]. Population Approach Group in Europe; 6\u20139 June, 2017; Budapest."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00765-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00765-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00765-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T23:05:02Z","timestamp":1588460702000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00765-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,4]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00765-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,4]]},"assertion":[{"value":"4 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Christine Xu and Vanaja Kanamaluru are employees of Sanofi Genzyme, and may hold stock and\/or stock options in the company. Yaming Su is a former employee of Sanofi Genzyme, and may hold stock and\/or stock options in the company. Anne Paccaly is an employee of Regeneron Pharmaceuticals, Inc., and may hold stock and\/or stock options in the company. None of the authors have any non-financial conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}